• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Etrials Pays $500K to Terminate Agreement with BioClinica

Etrials Pays $500K to Terminate Agreement with BioClinica

June 3, 2009
CenterWatch Staff

Only days after BioClinica increased its purchase offer to acquire etrials Worldwide and the two companies agreed to proceed with their acquisition agreement, that agreement has been terminated.

BioClinica increased its purchase offer last week after eClinical vendor etrials received an unsolicited offer from another company. etrials has now entered into a new merger agreement with that company, now identified as Merge Healthcare, at a cost of $500,000, plus reasonable out-of-pocket expenses,  to terminate the agreement with BioClinica.

"We have decided it would not be in the best interest of our shareholders to pursue this acquisition further. Although we are disappointed with the outcome, we will continue to actively look for other acquisitions that would add value and expand our eClinical service offerings," said BioClinica president and CEO Mark Weinstein in a company statement.

Under the terms of the acquisition agreement with Merge, a health IT solutions provider based in Milwaukee, Wisc., the sale will be consummated through a tender offer for all of the outstanding shares of etrials stock. The Merge tender offer consists of a mix of $0.80 in cash and 0.3448 shares of Merge common stock for each share of etrials common stock, representing an aggregate value of $1.70 per share. According to published reports, the sale price may be as much as $20 million.

The transaction is expected to close at the end of the third quarter.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing